TAO SHEN to Biomarkers, Tumor
This is a "connection" page, showing publications TAO SHEN has written about Biomarkers, Tumor.
Connection Strength
1.363
-
Development and functional validation of a disulfidoptosis-related gene prognostic model for lung adenocarcinoma based on bioinformatics and experimental validation. Front Immunol. 2025; 16:1540578.
Score: 0.513
-
Integrative machine learning frameworks to uncover specific protein signature in neuroendocrine cervical carcinoma. BMC Cancer. 2025 Jan 10; 25(1):57.
Score: 0.510
-
Screening and identification of versican as a sensitive biomarker and potential therapeutic target in basal cell carcinoma. Int J Med Sci. 2025; 22(10):2488-2501.
Score: 0.130
-
Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2. Front Immunol. 2023; 14:1155182.
Score: 0.114
-
CXCL8, overexpressed in colorectal cancer, enhances the resistance of colorectal cancer cells to anoikis. Cancer Lett. 2015 May 28; 361(1):22-32.
Score: 0.064
-
Multi-omics identification of a signature based on malignant cell-associated ligand-receptor genes for lung adenocarcinoma. BMC Cancer. 2024 Sep 12; 24(1):1138.
Score: 0.031